Amplia Therapeutics Limited Stock Fundamentals
| INNMF Stock | USD 0.06 0 7.41% |
Amplia Therapeutics Limited fundamentals help investors to digest information that contributes to Amplia Therapeutics' financial success or failures. It also enables traders to predict the movement of Amplia Pink Sheet. The fundamental analysis module provides a way to measure Amplia Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amplia Therapeutics pink sheet.
Amplia |
Amplia Therapeutics Limited Company Profit Margin Analysis
Amplia Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Amplia Therapeutics Profit Margin | (1.75) % |
Most of Amplia Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amplia Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Amplia Therapeutics Limited has a Profit Margin of -1.7502%. This is 84.39% lower than that of the Healthcare sector and 92.4% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 37.81% higher than that of the company.
Amplia Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amplia Therapeutics's current stock value. Our valuation model uses many indicators to compare Amplia Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amplia Therapeutics competition to find correlations between indicators driving Amplia Therapeutics's intrinsic value. More Info.Amplia Therapeutics Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amplia Therapeutics' earnings, one of the primary drivers of an investment's value.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Amplia Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.75) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 4.82 M | |||
| Shares Outstanding | 194.01 M | |||
| Shares Owned By Insiders | 22.09 % | |||
| Shares Owned By Institutions | 23.14 % | |||
| Price To Earning | (1.12) X | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 3.97 X | |||
| Revenue | 2.99 M | |||
| Gross Profit | 1.83 M | |||
| EBITDA | (3.64 M) | |||
| Net Income | (3.64 M) | |||
| Cash And Equivalents | 14.61 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 2.1 M | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 31.18 X | |||
| Book Value Per Share | 0.1 X | |||
| Cash Flow From Operations | (4.4 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 25 | |||
| Beta | 0.4 | |||
| Market Capitalization | 12.13 M | |||
| Total Asset | 24.48 M | |||
| Retained Earnings | (113 M) | |||
| Working Capital | 8 M | |||
| Current Asset | 9 M | |||
| Current Liabilities | 1000 K | |||
| Z Score | -2.6 | |||
| Net Asset | 24.48 M |
About Amplia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amplia Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amplia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amplia Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Innate Immunotherapeuti is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.